Evidence map›Paper›PMID 40162197›Full record

ArticleMDM policy & practice

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan.

Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J Smith, Nandita Kachru

Abstract read
In one paragraph

Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elise Chia-Hui TanDepartment of Health Service Administration, China Medical University, Taichung, Taiwan.
Alon YehoshuaGilead Sciences Inc., Foster City, CA, USA.
Sushanth JeyakumarMaple Health Group, New York, NY, USA.
Pongo PengGilead Sciences Inc., Foster City, CA, USA.
Amy LinGilead Sciences Inc., Foster City, CA, USA.
Nathaniel J SmithMaple Health Group, New York, NY, USA.ORCID https://orcid.org/0000-0002-9215-8109
Nandita KachruGilead Sciences Inc., Foster City, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highlights: The cost-effectiveness of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) and entecavir (ETV) was assessed in patients with chronic hepatitis B in Taiwan.TAF was associated with fewer liver disease events, fewer cases of bone and renal complications, and higher eAG and sAG seroconversion compared with TDF and ETV; TAF was found to be cost-effective compared with both treatments.

Indexed as

chronic hepatitis Bcost-effectiveness analysistenofovir alafenamidetenofovir disoproxil fumarate

Identifiers

PMID40162197
PMCPMC11954167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.